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MicroAbstract: 
Incidental findings on WBMRI in myeloma may necessitate additional 
investigations. Incidence, characterisation and significance of incidental findings 
at WBMRI in 100 patients with plasma cell disorders were calculated. 348 
findings were detected in 97/100 patients; 38/348 findings were indeterminate. 
No additional cancers were detected. Incidental findings are common but the 
majority can be characterized at WBMRI and are not significant.   
 
Abstract: 
Introduction/Background: 
Whole body magnetic resonance imaging (WBMRI) is currently recommended 
by guidelines for the assessment of myeloma. This will inevitably result in 
incidental findings. We aimed to assess the frequency of extraskeletal incidental 
findings and the added value of contrast-enhanced T1-weighted (CE T1-W) and 
diffusion-weighted (DWI) sequences for their characterisation in a single WBMRI 
examination. 
Materials and Methods: 
1.5T WBMRI was performed in 100 patients (53 female; median age of 65 years) 
with plasma cell disorders from January 2014 to July 2017. T2-weighted (T2-W) 
sequences were reviewed initially for incidental findings, followed by sequential 
review of T1-W, CE T1-W and DWI sequences for lesion characterisation. 
Descriptive statistics were undertaken. 
Results: 
348 incidental findings were detected in 97/100 (97% patients); only 38/348 
findings (10.9%) were indeterminate. T1-W sequences increased diagnostic 
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confidence in the characterisation of 12/38 (31.6%); CE T1-W sequences in the 
characterisation of 16 of 32 (50%); while DWI increased diagnostic confidence in 
21 of 38 (55.3%) compared to the T2-W sequence alone. 
Conclusion: 
Incidental findings are common but the majority are of no clinical consequence. 
No additional cancers were noted in our series. DWI and CE T1-W sequences 
increased diagnostic confidence in 50% of indeterminate findings; and may 
reduce the need for further investigation.  
 
Keywords: 
Multiple myeloma; Magnetic Resonance Imaging; Diffusion Magnetic Resonance 
Imaging; Whole Body Imaging. 
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Introduction: 
The revised International Myeloma Working Group (IMWG) Guidelines now 
state that the presence > 1 focal MRI bone lesion > 5 mm is diagnostic of 
myeloma [1]. IMWG also specifically advocate WBMRI in the initial assessment of 
smouldering myeloma as patients are at increased risk of progression to 
myeloma. With its excellent tissue contrast and high spatial resolution, WBMRI 
provides a comprehensive approach to skeletal and extra-skeletal assessment. 
WBMRI will define disease burden through the number and location of skeletal 
lesions, the pattern of disease, and the presence of extra-osseous sites as well as 
clinically significant complications such as fractures and cord/cauda equina 
compression.  
Thus clinical practice guidelines are changing. Whole body MRI (WBMRI) is now 
recommended in the United Kingdom (UK) by the National Institute for Health 
and Care Excellence (NICE) as the first-line imaging test for suspected and newly 
diagnosed myeloma [2]. The 2017 British Society of Haematology guidelines also 
recommend WBMRI as the first-line imaging test in asymptomatic patients with 
10-60% plasma cells on trephine biopsy or bone marrow aspirate or an M 
protein > 30g/L [3]. 
Incidental findings are inevitable with whole body studies and may require 
further investigations, adding to patient anxiety. Up to 58% of incidental findings 
may be indeterminate in nature [4]. We hypothesised that a comprehensive 
WBMRI protocol including T2-weighted (T2-W), T1-weighted (T1-W), contrast-
enhanced T1-weighted (CE T1-W) and diffusion-weighted (DWI) sequences will 
improve the characterisation of incidental findings and potentially reduce the 
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need for further investigations. Thus we aimed to determine 1) the frequency of 
incidental findings in patients undergoing WBMRI for plasma cell disorders in 
our institution; 2) their clinical significance; and 3) the added value of T1-W, CE 
T1W and DWI sequences in the characterisation of indeterminate findings. 
 
Materials and methods: 
Patients 
Institutional review board approval was obtained and informed consent waived 
for this retrospective audit of practice. 100 patients with suspected or proven 
plasma cell disorders underwent WBMRI between January 2014 and July 2017. 
There were 53 female, 47 male patients, median age of 65 years (range 38-90 
years) with the following confirmed diagnoses: myeloma = 63, smouldering 
myeloma = 11, monoclonal gammopathy of unknown significance (MGUS) = 12, 
plasmacytoma = 6 and other diagnoses = 8 (suspected myeloma = 3, amyloidosis 
= 3, lymphoma = 1, demyelinating neuropathy = 1).  
 
Imaging and image analysis 
WBMRI consisting of T2-W, T1-W, DWI (b-value=50 and 900s/mm2) and CE T1-
W sequences from the skull vertex to knees was performed at 1.5T (Magnetom 
Aera, Siemens Healthcare, Erlangen, Germany) (Table 1). WBMRI study duration 
was approximately 45 minutes. Intravenous contrast administration (20 mLs 
Dotarem) was only possible in 82/100 (82%) patients due to renal impairment. 
 
T2-W sequences were reviewed initially for incidental findings, followed by a 
dedicated review of T1-W, CE T1-W and DWI sequences including apparent 
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diffusion co-efficient (ADC) maps by a staff radiologist with 7 years of MRI 
experience. Findings, their site, and likely diagnoses were noted. These findings 
were also categorised as either I -common in asymptomatic subjects/not 
clinically significant, IIA -benign and potentially clinically significant, IIB -
indeterminate and potentially malignant, or III -requiring urgent clinical input, 
based on review of T2-W sequences.  
 
For indeterminate findings that could not be characterised initially on the T2-W 
sequence, the likelihood of malignancy was recorded for each additional 
sequence (T1-W, CE-T1W and DWI) as follows: I = benign, II = probably benign, 
III = indeterminate, IV = probably malignant, V = malignant.  
 
The diagnostic confidence for likely diagnosis was also scored for T1-W, CE T1-
W and DWI sequences independent of each other in order to ascertain the added 
value of each additional sequence for lesion characterisation compared to the 
initial T2-W sequence. 
 
Reference standard 
Electronic patient records were reviewed in order to confirm whether the 
incidental findings detected at WBMRI resulted in further investigations, 
including further imaging tests and biopsy and the final diagnosis. Where no 
further information was available, clinical consensus as to clinical significance 
and whether further management would have been undertaken was agreed by 2 
haematologists. Clinical significance was graded as follows: unknown, low 
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significance, moderate significance (meriting further routine investigation) and 
high significance (meriting urgent investigation). 
 
Statistical analysis: 
Descriptive statistics were undertaken using SPSS (Version 24, IBM, Armonk, 
New York, USA). 
 
Results: 
348 incidental findings were detected on the T2-W sequences in 97/100 (97%) 
patients, (median = 3 findings per patient, range = 1-9 findings). The most 
common findings are summarised in Table 2. 
 
197/348 (56.6%) findings were classified as category I (benign/not clinically 
significant), 113/348 (32.5%) findings were classified as category IIA (benign 
and potentially clinically significant) and 38/348 (10.9%) findings were 
classified as category IIB. (Indeterminate and potentially malignant). There were 
no category III (clinically urgent) findings.  
 
The category IIB (indeterminate) findings are summarised in Table 3 and were 
located at the following sites: liver (7), spleen (2), adrenal (5), prostate (5), 
lymph nodes (5) and others (14). Thirty-four patients had one indeterminate 
finding; 2 patients had 2 indeterminate findings; 2 patients had 3 and 4 
indeterminate findings respectively. 
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Each additional sequence (T1-W, CE T1-W or DWI) resulted in increased 
diagnostic confidence for lesion characterisation when compared with the initial 
T2-weighted imaging. T1-weighted Dixon sequences increased diagnostic 
confidence in the characterisation of 12/38 (31.6%) findings due to its ability to 
demonstrate microscopic fat and haemorrhage; 5 indeterminate adrenal lesions 
were confirmed as adrenal adenomas with the T1-W Dixon sequences. CE T1-W 
sequences, only possible in 82/100 (82%) patients due to renal impairment in 
the remaining patients, increased diagnostic confidence in characterisation of 16 
of 32 (50%) findings compared to T2-W imaging alone and was particularly 
helpful for hepatic and renal lesions. DWI sequences increased diagnostic 
confidence in characterisation of 21 of 38 (55.3%) findings compared to T2-W 
imaging alone. T1-weighted Dixon, DWI and CE T1-W sequences did not improve 
characterisation of 2 subcentimetre pulmonary nodules.  
 
In 16/38 (42.1%) patients further investigation of indeterminate findings was 
recommended (further imaging = 5, histology = 11). 8/16 (50%) patients were 
investigated further. For the remaining 8 findings, one patient died before 
further investigation could be undertaken. The cause of death was progressive 
myeloma and the hepatosplenic lesions likely represented extramedullary 
disease sites. Of the 7 findings not investigated initially, 5/7 findings scored as 
low clinical significance. 2/7 findings were scored as moderate by clinical 
consensus, for whom further investigations were recommended; transvaginal 
ultrasound in Patient 5, found to have incidental endometrial thickening, and 
serum PSA +/- histology in Patient 7 with possible incidental prostatic lesion 
(Table 4).  
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No additional new malignancies were detected in this cohort. There were 3 cases 
of known concurrent malignancy (prostate cancer (2) and parotid Warthin’s 
tumour (1)). There were also 2 cases of extramedullary plasmacytoma within 
lymph nodes. Following exclusion of the 3 cases of known malignancy, 19/35 
(54.3%) indeterminate findings could be fully characterised via T1-Dixon, DWI 
and/or CE T1-W sequences such that no further investigations were required. 
 
Discussion: 
Incidental findings are relatively common in patients with plasma cell disorders 
undergoing WBMRI, present in 97% of patients in our cohort. The majority could 
be characterised fully with a comprehensive protocol such that no further 
investigations were required. Over half of the detected incidental findings were 
classified as not clinically significant or common in asymptomatic subjects. No 
new malignancies were detected in our cohort although there were pre-existing 
malignancies and extra-osseous sites of disease. 
 
T1-W Dixon sequences were helpful in the characterisation of lesions containing 
microscopic fat e.g. adrenal adenoma, macroscopic fat e.g. lipoma and in the 
detection of haemorrhage e.g. haemorrhagic material within the uterine cavity 
and haemorrhagic renal cysts. CE T1-W sequences were particularly helpful in 
characterisation of hepatic and renal lesions. Diffusion-weighted sequences 
assisted in the characterisation of prostatic lesions, hepatic lesions and lymph 
nodes. 
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Our study reports a higher percentage of incidental findings than previously 
published WBMRI studies of various populations, where incidental findings have 
been found in up to 80% of patients [5]. In the general population-based Study of 
Health in Pomerania (SHIP), incidental findings were detected in 36.2% of 
participants (n= 2500), 5.9% of which were malignant [4]. In the SHIP study, 
incidental findings were categorised as either I -normal/common in 
asymptomatic subjects, II -requiring further medical evaluation or III -requiring 
immediate referral. In another study incidental findings were detected in 42% of 
neurofibromatosis patients (n=247) [6] whilst, amongst a cohort of lymphoma 
patients (n=119), 79.8% had one or more incidental finding although only 6% 
were classified as clinically significant [5].  
 
There is only one other study to date evaluating incidental findings in WBMRI in 
myeloma where incidental findings were detected in 38% of patients [7]. In this 
retrospective study the authors reviewed WBMRI (comprising axial DWI 
sequences with corresponding ADC maps and T1-W and T2-W sagittal whole 
spine sequences) in 110 patients. 70 incidental findings were documented, of 
which 14/70 (20%) were equivocal or indeterminate. Clinical 
correlation/review of previous imaging was recommended as the initial action in 
57% (8/14 patients) with indeterminate incidental findings and only 3% 
required further characterisation as the initial action.  
 
The comparatively higher incidental finding detection rate in our cohort 
compared with this study partly reflects the differences in imaging protocol. The 
WBMRI protocol utilised in the study by Wale et al only included axial DWI 
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sequences compared to our more comprehensive protocol of T2-W, T1-W, CE 
T1-W and DWI sequences. Greater standardisation of WBMRI protocols could 
reduce such variances. The greater proportion of incidental findings requiring 
further investigation in our cohort may also be partially attributed to variations 
in individual radiologist threshold for reporting some incidental findings and 
also intrinsic differences in the incidental findings encountered. For example, no 
prostatic lesions were reported in the study by Wale et al. 
 
There are no studies to date that have specifically addressed the value of 
individual sequences in characterising incidental findings. The value of diffusion-
weighted sequences in the baseline assessment of focal and diffuse marrow 
infiltration is clear (8) and there is growing evidence for its use in myeloma 
response assessment (9). Contrast-enhanced sequences are not utilised in all 
WBMRI protocols, particularly given the prevalence of renal impairment in this 
population, however studies have shown that they improve sensitivity for 
detection of bone lesions (10), hence the inclusion of post-contrast imaging in 
our WBMRI protocol. This study demonstrates that both DWI and CE T1-W 
imaging increased diagnostic confidence in characterisation of incidental 
findings. 
 
Nevertheless, there are limitations to this study. Incidental findings were 
recorded regardless of clinical importance, thus our detection rate is likely to 
exceed that of a typical clinical report. Secondly, due to its retrospective nature, 
it was not possible to determine if further investigation of indeterminate 
findings had been actioned in all patients, even after electronic patient record 
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review. However of the 7 cases identified, only 2 were considered of moderate 
clinical significance by clinical consensus. Additionally, only one reader 
performed the imaging analysis, thus intra and inter-observer variation could 
not be assessed. It is also theoretically possible that additional incidental 
findings could be demonstrated on supplementary sequences such as CE T1-W 
sequences e.g. hypervascular hepatosplenic lesions, however this potential issue 
was not encountered in our study cohort. Finally, the grading score used to 
assess malignancy likelihood of indeterminate findings has not been validated 
for use in previous studies. This study could be further improved by 
incorporating a second reader and utilizing a prospective approach.  
 
Conclusion: 
Incidental findings are relatively common in patients with plasma cell disorders 
undergoing WBMRI. The majority of findings are benign in nature and can be 
characterised fully with a comprehensive protocol, necessitating few additional 
investigations. Our findings should provide reassurance to clinicians requesting 
WBMRI.  
 
Clinical Practice Points: 
There has only been one previous study assessing frequency and significance of 
incidental findings at WBMRI in myeloma where incidental findings were 
detected in 38% of patients. In our study, the detection rate is significantly 
higher (97%). This difference may be explained by differences in imaging 
protocol and by variations in individual radiologist threshold for reporting some 
incidental findings.  
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The results of this study demonstrate that, whilst incidental findings are 
common at whole body MRI (WBMRI), the vast majority are not clinically 
significant. The inclusion of contrast-enhanced and diffusion-weighted 
sequences in WBMRI protocols substantially improves reader confidence in 
characterization of incidental findings, reducing the need for further additional 
investigations (potentially resulting in patient anxiety and additional healthcare 
costs).  
Our results should provide reassurance to clinicians requesting WBMRI with 
regards possible incidental findings, and provide further evidence to support 
inclusion of contrast-enhanced and diffusion-weighted sequences in WBMRI 
protocols, additional to their value in detection of bone disease in myeloma.  
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